Reported Reactions

Reactions

MedDRA preferred term · the wrong medicine was given

Wrong drug administered: adverse event reports recording this term

8,915 reports to FDA record it, 2005–2018; 0% of the database.

8,915
reports recording the term
0% of all reports
0
reports, 12 months to June 2026
0 in the 12 months before
48.9%
marked serious by the reporter
57.4% across all reports
5.4%
record death among outcomes, as reported
9.1% across all reports

8,915 reports in FDA's adverse event database record the MedDRA term "Wrong drug administered" (in plain words, the wrong medicine was given): 0% of all reports received between January 2005 and September 2018. Coders pick the term that best matches the reporter's description.

0 reports recorded it in the 12 months to June 2026, and none in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 48.9% are marked serious, 5.4% include death among the outcomes and 21.4% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Humalog, Humalog Mix75/25 and Lantus. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

011Jul 2021: 0Aug 2021: 0Sep 2021: 0Oct 2021: 0Nov 2021: 0Dec 2021: 02022Jan 2022: 0Feb 2022: 0Mar 2022: 0Apr 2022: 0May 2022: 0Jun 2022: 0Jul 2022: 0Aug 2022: 0Sep 2022: 0Oct 2022: 0Nov 2022: 0Dec 2022: 02023Jan 2023: 0Feb 2023: 0Mar 2023: 0Apr 2023: 0May 2023: 0Jun 2023: 0Jul 2023: 0Aug 2023: 0Sep 2023: 0Oct 2023: 0Nov 2023: 0Dec 2023: 02024Jan 2024: 0Feb 2024: 0Mar 2024: 0Apr 2024: 0May 2024: 0Jun 2024: 0Jul 2024: 0Aug 2024: 0Sep 2024: 0Oct 2024: 0Nov 2024: 0Dec 2024: 02025Jan 2025: 0Feb 2025: 0Mar 2025: 0Apr 2025: 0May 2025: 0Jun 2025: 0Jul 2025: 0Aug 2025: 0Sep 2025: 0Oct 2025: 0Nov 2025: 0Dec 2025: 02026Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

DrugClassReports with this termShare of the drug's own reports
HumalogInsulin analog1,0831.5%
Humalog Mix75/25Insulin analog3574.4%
LantusInsulin analog3350.9%
NexiumProton pump inhibitor2300.3%
Dianeal Low Calcium Peritoneal Dialysis Solution with Dextrose—2080.3%
NovologInsulin analog1761.2%
SeroquelAtypical antipsychotic1450.3%
Humulin NInsulin1441.3%
Solostar—1431.2%
Humulin RInsulin1311.6%
Humira—990%
Cetirizine hydrochlorideHistamine-1 receptor antagonist980.5%
ZyrtecHistamine-1 receptor antagonist970.5%
ApidraInsulin analog902.5%
Dianeal Low Calcium—850.3%
Lantus SolostarInsulin analog830.2%
Humulin 70/30Insulin721%
IbuprofenNonsteroidal anti-inflammatory drug710.1%
LevemirInsulin analog660.5%
Allegra—640.5%
Insulin lisproInsulin analog620.8%
Apidra SoloStarInsulin analog614.4%
Methergine—6115.1%
ProliaRANK ligand inhibitor610%
ExtranealOsmotic laxative600.2%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

ClassReports with this termShare of class reportsMedian drug in class
Insulin analog2,5110.9%0.3%
Insulin4391.2%1%
Atypical antipsychotic3820.1%0%
Proton pump inhibitor3650.1%0%
Histamine-1 receptor antagonist3070.2%0%
Nonsteroidal anti-inflammatory drug2940.1%0%
Opioid agonist1710%0%
Osmotic laxative1260.1%0%
Corticosteroid1230%0%
Serotonin reuptake inhibitor1160%0%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 23.9%348
2 to 113.9%346
12 to 171.6%145
18 to 449.5%846
45 to 6415.2%1,356
65 to 749.2%822
75 and over9.1%809
Age not given47.6%4,243

Patient sex

Female48.6%4,335
Male35.2%3,136
Not given16.2%1,444

Grey bar: all 20,646,523 reports in the database. 78.5% of these reports give the United States as the country.

Questions about "Wrong drug administered"

What does "Wrong drug administered" mean in an adverse event report?

In plain language: the wrong medicine was given. It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record wrong drug administered?

8,915 reports through June 2026 (0% of all reports), 0 of them in the latest 12 months.

Which drugs appear most often in these reports?

Humalog (1,083), Humalog Mix75/25 (357), Lantus (335), Nexium (230) and Dianeal Low Calcium Peritoneal Dialysis Solution with Dextrose (208). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.